Human epidermal growth factor receptor 2 (HER2), as a prognostic and predictive factor, is overexpressed as a result of the amplification of the ERBB2 gene, part of the epidermal growth receptor factor (EGFR) family, in about 15% of breast cancers [2,3]. This evidence concerns the gene EGFR and breast carcinoma.